Substituted indoles as potent and orally active 5-lipoxygenase activating protein (FLAP) inhibitors

被引:12
|
作者
Frenette, R
Hutchinson, JH
Léger, S
Thérien, M
Brideau, C
Chan, CC
Charleson, S
Ethier, D
Guay, J
Jones, TR
McAuliffe, M
Piechuta, H
Riendeau, D
Tagari, P
Girard, Y
机构
[1] Merck Frosst Ctr Therapeut Res, Pointe Claire, PQ H9R 4P8, Canada
[2] Merck & Co Inc, W Point, PA 19486 USA
关键词
D O I
10.1016/S0960-894X(99)00399-6
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
This paper reports on the SAR investigation of inhibitors of 5-lipoxygenase activating protein (FLAP) based on MK-0591. Emphasis was made on modifications to the nature of the link between the indole and the quinoline moieties, to the substitution pattern around the two heterocycles and to possible replacements of the quinoline moiety. Lead optimization culminated in (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(pyridin-2-ylmethoxy)-indol-2-yl]-2,2-dimethylpropanoic acid (18k), as a potent inhibitor of leukotriene biosynthesis that is well absorbed and active in functional models. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:2391 / 2396
页数:6
相关论文
共 50 条
  • [31] NOVEL SERIES OF POTENT 5-LIPOXYGENASE INHIBITORS
    HITE, GA
    SUAREZ, T
    CHO, HL
    BERTSCH, BA
    TOWNER, RD
    WANG, L
    HO, PPK
    SNYDER, DW
    MIHELICH, ED
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1993, 205 : 142 - MIDI
  • [32] Development of CMI-977 as a potent and orally active 5-lipoxygenase inhibitor.
    Cai, X
    Cheah, S
    Chen, SM
    Eckman, J
    Ellis, J
    Fisher, R
    Fura, A
    Grewal, G
    Hussion, S
    Ip, S
    Killian, DB
    LibertineGarahan, L
    Lounsbury, H
    Qian, CG
    Scannell, RT
    Yaeger, D
    Wypij, DM
    Yeh, CG
    Young, MA
    Yu, SX
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 214 : 214 - MEDI
  • [33] QSAR Study on 5-Lipoxygenase Activating Protein (FLAP) Inhibitors: The Derivatives of 2,2-Bisaryl-Bicycloheptane
    Sharma, Brij Kishore
    Pilania, Pradeep
    Singh, Prithvi
    LETTERS IN DRUG DESIGN & DISCOVERY, 2011, 8 (01) : 32 - 43
  • [34] 5-lipoxygenase and FLAP
    Peters-Golden, M
    Brock, TG
    PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 2003, 69 (2-3): : 99 - 109
  • [35] Effects of MK-886, a 5-lipoxygenase activating protein (FLAP) inhibitor, and 5-lipoxygenase deficiency on the forced swimming behavior of mice
    Uz, Tolga
    Dimitrijevic, Nikola
    Imbesi, Marta
    Manev, Hari
    Manev, Radmila
    NEUROSCIENCE LETTERS, 2008, 436 (02) : 269 - 272
  • [36] SYNTHESIS AND DEVELOPMENT OF L-670,630 AS A POTENT AND ORALLY ACTIVE INHIBITOR OF 5-LIPOXYGENASE
    THERIEN, M
    LAU, CK
    BELANGER, PC
    DUFRESNE, C
    SCHEIGETZ, J
    FITZSIMMONS, B
    RIENDEAU, D
    DENIS, D
    GUAY, J
    CHARLESON, S
    PIECHUTA, H
    MCFARLANE, CS
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1991, 202 : 180 - MEDI
  • [37] ICI D2148 - A POTENT, ORALLY-ACTIVE NONREDOX INHIBITOR OF 5-LIPOXYGENASE
    FOSTER, SJ
    CRAWLEY, GC
    WALKER, ERH
    MCMILLAN, RM
    BRITISH JOURNAL OF PHARMACOLOGY, 1992, 106 : P71 - P71
  • [38] Discovery of AZD5718, a novel 5-lipoxygenase activating protein (FLAP) inhibitor
    Lemurell, Malin
    Pettersen, Daniel
    Ulander, Johan
    Hayes, Martin
    Whatling, Carl
    Swanson, Marianne
    Broddefalk, Johan
    Emtenas, Hans
    Lindstedt, Eva-Lotte
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256
  • [39] Interleukin-5 enhances expression of 5-lipoxygenase activating protein (FLAP), but not of 5-lipoxygenase (5-LO), in human blood eosinophils.
    Cowburn, AS
    Seymour, ML
    Holgate, ST
    Sampson, AP
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 101 (01) : S230 - S231
  • [40] Potent Inhibitors of 5-Lipoxygenase Identified using Pseudoreceptors
    Roedl, Carmen B.
    Tanrikulu, Yusuf
    Wisniewska, Joanna M.
    Proschak, Ewgenij
    Schneider, Gisbert
    Steinhilber, Dieter
    Hofmann, Bettina
    CHEMMEDCHEM, 2011, 6 (06) : 1001 - 1005